TY - JOUR
T1 - Lung cancer
T2 - Potential targets for immunotherapy
AU - Tartour, Eric
AU - Zitvogel, Laurence
N1 - Funding Information:
This work was supported by grants from Université Paris Descartes, the Ligue contre le Cancer, the Agence Nationale de la Recherche (ANR), the Association pour la Recherche contre le Cancer (ARC), the Canceropole and Region Ile de France, the Institut National du Cancer (INCA), the Labex Immuno-Oncology, Site de Recherche Intégrée sur le Cancer Stratified Oncology Cell DNA Repair And Tumor immune Elimination (SIRIC SOCRATES), Paris Alliance of Cancer Research Institutes (PACRI), and CAncer Research and PErsonalized Medicine (CARPEM).
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Lung cancer is the most common cause of cancer-related mortality worldwide and a therapeutic challenge. Recent success with antibodies blocking immune checkpoints in non-small-cell lung cancers (NSCLC) highlights the potential of immunotherapy for lung cancer treatment, and the need for trials of combination regimens of immunotherapy plus chemotherapy that lead to immunogenic cell death. Here, we review the development of immunogenic cytotoxic compounds, vaccines, and antibodies in NSCLC, in view of their integration into personalised oncology.
AB - Lung cancer is the most common cause of cancer-related mortality worldwide and a therapeutic challenge. Recent success with antibodies blocking immune checkpoints in non-small-cell lung cancers (NSCLC) highlights the potential of immunotherapy for lung cancer treatment, and the need for trials of combination regimens of immunotherapy plus chemotherapy that lead to immunogenic cell death. Here, we review the development of immunogenic cytotoxic compounds, vaccines, and antibodies in NSCLC, in view of their integration into personalised oncology.
UR - http://www.scopus.com/inward/record.url?scp=84883450101&partnerID=8YFLogxK
U2 - 10.1016/S2213-2600(13)70159-0
DO - 10.1016/S2213-2600(13)70159-0
M3 - Review article
C2 - 24461616
AN - SCOPUS:84883450101
SN - 2213-2600
VL - 1
SP - 551
EP - 563
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 7
ER -